A novel approach for studying angiogenesis: A human skin equivalent with a capillary-like network

Angiolillo AL, Kanegane H, Sgadari C, Reaman GH, Tosato G. Interleukin-15 promotes angiogenesis in vivo. Biochem Biophys Res Commun. 1997;233:231–7. Arthur WT, Vernon RB, Sage EH, Reed MJ. Growth factors reverse the impaired sprouting of microvessels from aged mice. Microvasc Res. 1998;55:260–70. Ballaun C, Weninger W, Uthman A, Weich H, Tschachler E. Human keratinocytes express the three major splice forms of vascular endothelial growth factor. J Invest Dermatol. 1995;104:7–10. Barillari G, Albonici L, Franzese O et al. The basic residues of placenta growth factor type 2 retrieve sequestered angiogenic factors into a soluble form: implications for tumor angiogenesis. Am J Pathol. 1998;152:1161–66. Benelli U, Bocci G, Danesi R et al. The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp Eye Res. 1998;67:133–42. Black AF, Berthod F, L'Heureux N, Germain L, Auger FA. In vitro reconstruction of a human capillary-like network in a tissue-engineered skin equivalent. FASEB J. 1998;12:1331–40. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αvβ3 for angiogenesis. Science. 1994;264:569–71. Cao Y, O'Reilly MS, Marshall B, Flynn E, Ji RW, Folkman J. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases. J Clin Invest. 1998;101:1055–63. Chalupowicz DG, Chowdhury ZA, Bach TL, Barsigian C, Martinez J. Fibrin II induces endothelial cell capillary tube formation. J Cell Biol. 1995;130:207–15. Cheresh DA. Death to a blood vessel, death to a tumor. Nature Med. 1998;4:395–6. Ching LM, Browne WL, Tchernegovski R, Gregory T, Baguley BC, Palmer BD. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the antitumor agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumor necrosis factor-alpha and enhancement of anti-tumor activity. Br J Cancer. 1998;78:336–43. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 1997;57:1814–19. Clapp C, Martial JA, Guzman RC, Rentier-Delure F, Weiner RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology. 1993;133:1292–9. Cockerill GW, Gamble JR, Vadas MA. Angiogenesis: models and modulators. Int Rev Cytol. 1995;159:113–60. Cornelius LA, Nehring LC, Roby JD, Parks WC, Welgus HG. Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration. J Invest Dermatol. 1995;105:170–6. Coughlin CM, Salhany KE, Wysocka M et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J Clin Invest. 1998;101:1441–52. Damour O, Augustin C, Black AF. Applications of reconstructed skin models in pharmaco-toxicological trials. Med Biol Eng Comput. 1998;6:825–32. Deed R, Rooney P, Kumar P et al. Early-response gene signaling is induced by angiogenic oligosaccharides of hyaluronan in endothelial cells. Inhibition by non-angiogenic, high molecular weight hyaluronan. Int J Cancer. 1997;10:251–6. Dinney CP, Bielenbreg DR, Perrotte P et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res. 1998;58:808–14. Dobryszycka W. Biological functions of haptoglobin — new pieces to an old puzzle. Eur J Clin Chem Clin Biochem. 1997;35:647–54. Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235:442–7. Folkman J, Weisz PB, Joullie MM, Li WW, Ewing WR. Control of angiogenesis with synthetic heparin substitutes. Science. 1989a;243:1490–3. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 1989b;339:58–62. Frank S, Hübner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem. 1995;270:12607–13. Fukushi J, Morisaki T, Shono T et al. Novel biological functions of interleukin 4: formation of tube-like structures by vascular endothelial cells in vitro and angiogenesis in vivo. Biochem Biophys Res Commun. 1998;250:444–8. Good DJ, Polverini PJ, Rastinejad F et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA. 1990;87:6624–8. Herbert JM, Cottineau M, Driot F, Pereillo JM, Maffrand JP. Activity of pentosan polysulfate and derived compounds on vascular endothelial cell proliferation and migration induced by acidic and basic FGF in vitro. Biochem Pharmacol. 1988;37:4281–8. Hu GF. Neomycin inhibits angiogenin-induced angiogenesis. Proc Natl Acad Sci USA. 1998;95:9791–5. Ingber DE, Folkman J. Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. J Cell Biol. 1989a;109:317–30. Ingber DE, Folkman J. How does extracellular matrix control capillary morphogenesis? Cell. 1989b;58:803–5. Ingber D, Fujita T, Kishimoto S et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature. 1990;348:555–7. Ito K, Abe T, Tomita M et al. Anti-angiogenic activity of arachidonic acid metabolism inhibitors in angiogenesis model systems involving human microvascular endothelial cells and neovascularization in mice. Int J Cancer. 1993;55:660–6. Jackson JR, Bolognese B, Hillegass L et al. Pharmacological effects of SB220025, a selective inhibitor of P38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J Pharmacol Exp Ther. 1998;284:687–92. Kohn EC, Alessandro R, Spoonster J, Wersto RP, Liotta LA. Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci USA. 1995;92(5):1307–11. Kruse FE, Joussen AM, Rohrschneider K, Becker MD, Volker HE. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 1998;235:461–6. Kubota Y, Kleinman HK, Martin GR, Lawley T. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells in capillary-like structure. J Cell Biol. 1988;107:1589–98. Majewski S, Skopinska M, Marczak M, Szmurlo A, Bollag W, Jablonska S. Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. J Invest Dermatol Symp Proc. 1996;1:97–101. Malinda KM, Sidhu GS, Banaudha KK et al. Thymosin alpha 1 stimulates endothelial cell migration, angiogenesis, and wound healing. J Immunol. 1998;160:1001–6. Mallery SR, Lantry LE, Toms MC et al. Human microvascular endothelial cell-extracellular matrix interaction in cellular growth state determination. Cell Tissue Res. 1994;279:37–45. Manetti F, Capello V, Botta M et al. Synthesis and binding mode of heterocyclic analogues of suramin inhibiting the human basic fibroblast growth factor. Bioorg Med.Chem. 1998;6:947–58. Meredith JE, Fazeli B Jr, Schwartz MA. The extracellular matrix as a cell survival factor. Mol Biol Cell. 1993;4:953–61. Michel M, Germain L, Belanger PM, Auger FA. Functional evaluation of anchored skin equivalent cultured in vitro: percutaneous absorption studies and lipid analysis. Pharm Res. 1995;12:455–8. Moghaddam A, Zhang HT, Fan TP et al. Thymidine phosphorylase is angiogenic and promotes tumor growth. Proc Natl Acad Sci USA. 1995;82:998–1002. Mohammadi M, Froum S, Hamby JM et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 1998;17:5896–904. Montesano R, Orci L. Tumor-promoting phorbol ester induce angiogenesis in vitro. Cell. 1985;42:469–77. Montesano R, Kumar S, Orci L, Pepper MS. Synergistic affect of hyaluronan oligosaccharides and vascular endothelial growth factor on angiogenesis in vitro. Lab Invest. 1996;75:249–62. Montesano R, Soriano JV, Pepper M, Orci L. Induction of epithelial branching tubulogenesis in vitro. J Cell Physiol. 1997;173:152–61. Nicosia RF, Lin YJ, Hazelton D, Qian X. Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor. Am J Pathol. 1997;151:1379–86. Okada N, Fushimi M, Nagata Y et al. Evaluation of angiogenic inhibitors with an in vivo quantitative angiogenesis method using agarose microencapsulation and mouse hemoglobin enzyme-linked immunosorbent assay. Jpn J Cancer Res. 1996;87:952–7. Ono M, Kawahara N, Goto D et al. Inhibition of tumor growth and neovascularization by an anti gastric ulcer agent. Cancer Res. 1996;56:1512. O'Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277–85. Pepper MS, Ferrara N, Orci L, Montesano R. Potent synergism between vascular endothelial growth factor and basic fibroblast growth factor in the induction of angiogenesis in vitro. Biochem Biophys Res Commun. 1992;189:824–31. Pluda JM, Parkinson DR. Clinical implication of tumor-associated neovascularization and current antiangiogenic strategies of the treatment of malignancies of pancreas. Cancer. 1996;78:680–7. Polverini PJ. Cellular adhesion molecules. Newly identified mediators of angiogenesis. Am J Pathol. 1996;148:1023–9. Re F, Zanetti A, Siroti M et al. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. J Cell Biol. 1994;127:537–46. Regnier M, Staquet MJ, Schmitt D, Schmidt R. Integration of Langerhans cells into a pigmented reconstructed human epidermis. J Invest Dermatol. 1997;109:510–12. Roberts AB, Sporn MB, Assoian RK et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA. 1986;83:4167–71. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin αvβ3 in the disruption of the tumor vasculature induced by TNF and INFγ. Nature Med. 1998;4:408–14. Sakamoto T, Ishibashi T, Kimura H et al. Effect of telogalan sodium on angiogenesis in vitro by choroidal endothelial cells. Invest Ophthalmol. 1995;36:1076–83. Sakkoula E, Pipili-Synetos E, Maragoudakis ME. Involvement of nitric oxide in the inhibition of angiogenesis by interleukin 2. Br J Pharmacol. 1997;122:793–5. Sasisekharan R, Moses MA, Nugent MA, Cooney CL, Langer R. Heparinase inhibits neovascularization. Proc Natl Acad Sci USA. 1994;9:1524–8. Schreiber AB, Winkler ME, Derynck R. Transforming growth factor alpha: a more potent angiogenic factor than epidermal growth factor. Science. 1986;232:1250–3. Seghezzi G, Patel S, Ren CJ et al. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 1998;141:1659–73. Strydom DJ. The angiogenins. Cell Mol Life Sci. 1998;54:811–24. Sunderkotter C, Goebeler M, Schulze-Osthoff K, Bhardwaj R, Sorg C. Macrophage-derived angiogenesis factors. Pharmacol Ther. 1991;51:195–216. Suri C, Jones PF, Patan S et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87:1171–80. Swerlick RA, Lawley TJ. Role of microvascular endothelial cells in inflammation. J Invest Dermatol. 1993;100:111–15S. Tanaka T, Yoshinobu M, Wen P, Kufe DW, Fine HA. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nature Med. 1997;3:437–42. Van Belle E, Witzenbichler B, Chen D et al. Potential angiogenic effect of scatter factor/hepatocyte growth factor: the case for paracrine amplification of angiogenesis. Circulation. 1998;97:381–90. Vernon RB, Sage EH. Between molecules and morphology. Extracellular matrix and creation of vascular form. Am J Pathol. 1995;147:873–83. Villaschi S, Nicosia RF. Paracrine interactions between fibroblasts and endothelial cells in a serum-free coculture model: modulation of angiogenesis and collagen gel contraction. Lab Invest. 1994;71:291–9. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in vivo by interleukin-12. J. Natl Cancer Inst. 1995;87:581–6. Volpert OV, Ward WF, Lingen MW et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest. 1996;98:671–9. Wamil BD, Thurman GB, Sundell HW et al. Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor-inhibiting anti-neovascularization agent, evaluated in phase I clinical trial. J Cancer Res Clin Oncol. 1997;123:173–9. Weiss JB, McLaughlin B. Endothelial cell stimulating angiogenesis factor. Int J Biochem Cell Biol. 1998;30:423–7. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997;15:61–75. Woltering EA, Watson JC, Alperin-Lea RC et al. Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs. 1997;15:77–86. Yoshida S, Ono M, Shono T et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol. 1997;17:4015–23.